中医药联合小剂量靶向药治疗骶尾部脊索瘤1例
Traditional Chinese medicine combined with low-dose anlotinib therapy for chordoma: A case report
- 现代中医临床 2021年28卷第3期 页码：73-76
- 作者机构：
1.北京中医药大学 北京 100029
2.中国中医科学院西苑医院
3.北京中医药大学厦门医院
- 作者简介：
赵娜，女，在读博士生
# 杨宇飞，女，博士，主任医师，博士生导师，E-mail：yyf93@vip.sina.com
- 基金信息：
DOI：10.3969/j.issn.2095-6606.2021.03.017
中图分类号： R273纸质出版日期：2021-05-30，
收稿日期：2020-08-02，
- 稿件说明：
移动端阅览
赵娜, 裴晓华, 杨宇飞. 中医药联合小剂量靶向药治疗骶尾部脊索瘤1例[J]. 现代中医临床, 2021,28(3):73-76.
Na Zhao, Xiaohua Pei, Yufei Yang. Traditional Chinese medicine combined with low-dose anlotinib therapy for chordoma: A case report[J]. Modern Chinese Clinical Medicine, 2021,28(3):73-76.
赵娜, 裴晓华, 杨宇飞. 中医药联合小剂量靶向药治疗骶尾部脊索瘤1例[J]. 现代中医临床, 2021,28(3):73-76. DOI： 10.3969/j.issn.2095-6606.2021.03.017.
Na Zhao, Xiaohua Pei, Yufei Yang. Traditional Chinese medicine combined with low-dose anlotinib therapy for chordoma: A case report[J]. Modern Chinese Clinical Medicine, 2021,28(3):73-76. DOI： 10.3969/j.issn.2095-6606.2021.03.017.
摘要
脊索瘤是一种罕见的骨肿瘤亚型，广泛切除加放疗是主要治疗手段。脊索瘤的全身治疗尚缺乏明确有效的强烈推荐药物，可以尝试靶向治疗。中国中医科学院西苑医院杨宇飞教授在脏腑本虚与肿瘤标实辨证基础上，准确把握肿瘤发展不同阶段，针对肿瘤、临床症状、靶向治疗副反应、转移部位全方位考虑，靶向药作为中医辨证后的抗肿瘤手段之一，中西医并重治疗脊索瘤，临床收效满意，附验案一则。
Abstract
Chordoma is a rare subtype of bone cancer. Wide resection with negative surgical margins and radiotherapy are the main effective treatment methods. Although there is no preferred regimen for chordoma
the targeted therapy can still be recommended. On the basis of traditional Chinese medicine (TCM) syndrome differentiation and treatment
Professor Yang Yufei combines TCM treatment with the low-dose targeted therapy to achieve PFS for 12 months in a chordoma case. This article may help inherit valuable experience of TCM experts and take advantage of TCM in the clinical practice for chordoma.
关键词
脊索瘤辨证论治中医治疗靶向治疗
Keywords
chordomaTCM syndrome differentiation and treatmentTCM treatmenttargeted therapy
references
YOUNG VA, CURTIS KM, TEMPLE HT, et al. Characteristics and Patterns of Metastatic Disease from Chordoma[J].Sarcoma, 2015:517-657.
GEORGE B, BRESSON D, HERMAN P, et al. Chordomas: A Review[J].Neurosurg Clin N Am, 2015, 26(3):437-452.
SMOLL N R, GAUTSCHI O P, RADOVANOVIC I, et al.Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population[J].Cancer, 2013,119(11):2029-2037.
SCIUBBA D M, CHI J H, RHINES L D, et al. Chordoma of the spinal column[J].Neurosurg Clin N Am, 2008, 19(1):5-15.
NCCN. The NCCN Clinical Practice Guidelines in Oncology Bone Cancer (Version 1.2020)[EB/OL].Fort Washington: NCCN, 2020[2019－8－12]. http: //www.nccw.org.
BERGH P, KINDBLOM L G, GUNTERBERG B, et al.Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients[J].Cancer, 2000, 88(9):2122-2134.
CHEN KW, YANG HL, LU J, et al.Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients[J].Spinal Cord, 2010, 48(2):166-171.
STACCHIOTTI S, CASALI P G, LO VULLO S, et al.Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers[J].Ann Surg Oncol, 2010,17(1):211-219.
RUGGIERI P, ANGELINI A, USSIA G, et al.Surgical margins and local control in resection of sacral chordomas[J].Clin Orthop Relat Res. 2010, 468(11):2939-2947.
廖锋，牛晓辉. 骶骨脊索瘤的治疗现状与进展[J].中华骨科杂志，2014, 34(11):1167-1173.
ROTONDO R L, FOLKERT W, LIEBSCH N J, et al.High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors[J].J Neurosurg Spine, 2015, 23(6):788-797.
UHL M, EDLER L, JENSEN A D, et al.Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol[J].Radiat Oncol, 2014, 29(9):100.
MIMA M, DEMIZU Y, JIN D, et al.Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma[J].Br J Radiol, 2014,87(1033):20130512.
YORK JE, KACZARAJ A, ABI-SAID D, et al.Sacral chordoma: 40-year experience at a major cancer center[J].Neurosurgery, 1999,44(1):74-9; discussion 79-80.
COLIA V, STACCHIOTTI S. Medical treatment of advanced chordomas[J].Eur J Cancer, 2017, 83:220-228.
YANG C, HORNICEK F J, WOOD K B, et al.Characterization and analysis of human chordoma cell lines[J].Spine, 2010, 35(13):1257-1264.
SéGALINY A I, TELLEZ-GABRIEL M, HEYMANN M F, et al.Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers[J].J Bone Oncol, 2015, 4(1):1-12.
AKHAVAN-SIGARI R, ABILI M, GAAB M R, et al.Immunohistochemical expression of receptor tyrosine kinase PDGFR-α，c-Met, and EGFR in skull base chordoma[J].Neurosurg Rev, 2015,38(1):89-98; discussion 98-9.
FASIG J H, DUPONT W D, LAFLEUR B J, et al.Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma[J].Neuropathol Appl Neurobiol, 2008, 34(1):95-104.
SHALABY A, PRESNEAU N, YE H, et al.The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target[J].J Pathol. 2011 Feb;223(3):336-346.
LINDéN O, STENBERG L, KJELLéN E. Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib[J].Acta Oncol, 2009,48(1):158-159.
LAUNAY S G, CHETAILLE B, MEDINA F, et al.Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review[J].BMC Cancer, 2011,11:423.
NOOR A, BINDAL P, RAMIREZ M, et al.Chordoma: A Case Report and Review of Literature[J].Am J Case Rep, 2020 Jan 23;21:e918927.
STACCHIOTTI S, LONGHI A, FERRARESI V, et al.Phase II study of imatinib in advanced chordoma[J].J Clin Oncol, 2012, 30(9):914-920.
HINDI N, CASALI P G, MOROSI C, et al.Imatinib in advanced chordoma: a retrospective case series analysis[J].Eur J Cancer, 2015,51(17):2609-2614.
0
浏览量
9
下载量
0
CSCD
- 网络PDF下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies